SLC5A2 and type 2 diabetes mellitus: The data on medication elimination and reduction, particularly for GLP-1 receptor agonists, SGLT2 inhibitors, and DPP4 inhibitors, highlights the potential of the DT intervention to alleviate some of the pharmacological burden for individuals with T2D (Fig. 3).